Voyager Therapeutics (NASDAQ: VYGR) revenue
Voyager Therapeutics reported revenue of $40.4m for fiscal 2025, 49.5% less than in fiscal 2024 ($80.0m). Since fiscal 2016 its revenue has grown by 183.9%, an average growth of 12.3% a year.
Voyager Therapeutics's revenue has fallen for 2 years in a row, and its best year of the last 10 was fiscal 2023. The biggest drop was in fiscal 2021, −78.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $40.4m | −49.5% | −$131.8m | −326.6% |
| 2024 | $80.0m | −68.0% | −$83.3m | −104.1% |
| 2023 | $250.0m | +511.2% | $122.0m | 48.8% |
| 2022 | $40.9m | +9.3% | −$50.8m | −124.3% |
| 2021 | $37.4m | −78.1% | −$73.6m | −196.8% |
| 2020 | $171.1m | +63.9% | $27.4m | 16.0% |
| 2019 | $104.4m | +1,270.1% | −$51.7m | −49.5% |
| 2018 | $7.6m | −24.8% | −$91.1m | −1,195.6% |
| 2017 | $10.1m | −28.7% | −$71.9m | −709.1% |
| 2016 | $14.2m | — | −$41.3m | −290.4% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Voyager Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Voyager Therapeutics ranks 339th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Voyager Therapeutics, −49.5%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 337th | Editas Medicine | $40.5m | 25.4% |
| 338th | Alpha Teknova | $40.5m | 7.4% |
| 339th | Voyager Therapeutics | $40.4m | −49.5% |
| 340th | Kymera Therapeutics | $39.2m | −16.7% |
| 341st | Utah Medical Products | $38.5m | −5.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Voyager Therapeutics
- How much revenue did Voyager Therapeutics make in fiscal 2025?
- Voyager Therapeutics reported revenue of $40.4m for fiscal 2025, compared with $80.0m in fiscal 2024.
- How much has the revenue of Voyager Therapeutics grown?
- Between fiscal 2016 and fiscal 2025 it went from $14.2m to $40.4m: 183.9% more, an average growth of 12.3% a year.
- What was the best year for revenue at Voyager Therapeutics?
- Of its last 10 fiscal years, fiscal 2023, with $250.0m.
- Where does Voyager Therapeutics rank in its sector by revenue?
- It ranks 339th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Voyager Therapeutics come from?
- From the annual report (Form 10-K) that Voyager Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Voyager Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Voyager Therapeutics: the Voyager Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.